SynthesisFrontiers in medicine2022
Serum creatinine/cystatin C ratio as a muscle mass evaluating tool and prognostic indicator for hospitalized patients: A meta-analysis.
Synthesis in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pretreatment creatinine-to-cystatin c ratio as a prognostic marker in digestive tract cancers: a meta-analysis with reconstructed individual patient data and trial sequential analysis.Frontiers in nutrition · 2026Pooled it
- Sarcopenia defined by serum creatinine and cystatin C predicts poor survival outcomes in patients with cancers.BMC geriatrics · 2025Pooled it
- Creatinine-to-cystatin C ratio as muscle assessment tool and predictive value for mortality and sarcopenia in patients with chronic kidney disease: a meta-analysis.Frontiers in nutrition · 2025Pooled it
- Oral alkalinizing supplementation suppressed intrarenal reactive oxidative stress in mild-stage chronic kidney disease: a randomized cohort study.Clinical and experimental nephrology · 2024Trial
- Relationship Between Sarcopenia and Intensive Blood Pressure Control Efficacy and Safety: A Secondary Analysis of SPRINT.Hypertension (Dallas, Tex. : 1979) · 2024Trial
- Serum Creatinine/Cystatin C-Based Muscle Indices for Sarcopenia and Graft Failure After Living Donor Liver Transplantation.Journal of clinical medicine · 2026Article
- Prevalence of Sarcopenia in Patients with Hip Osteoarthritis Undergoing Total Hip Arthroplasty: A Cross-Sectional Study Based on EWGSOP2 Criteria.Journal of clinical medicine · 2026Article
- Serum creatinine to cystatin C ratio and risk of incident digestive diseases in middle-aged and older adults: a prospective national cohort study.Scientific reports · 2026Article
- Unravelling Sarcopenia in Chronic Kidney Disease: From Pathogenesis to Diagnosis and Therapeutics.Diagnostics (Basel, Switzerland) · 2026Review
- The CCR/WC ratio as a predictor of dyslipidemia and Its mediating effect on hypertension in middle-aged and older adults.BMC cardiovascular disorders · 2026Article
- Causal relationship between serum creatinine levels and bone mineral density: A Mendelian randomization study.Medicine · 2026Article
- Serum creatinine to cystatin C ratio as a biomarker for monitoring motor-function in children with spinal muscular atrophy treated with nusinersen: a retrospective cohort study.BMC neurology · 2026Article
- The value of serum creatinine-to-cystatin C ratio in newly diagnosed ketosis-prone diabetes.Endocrine connections · 2026Article
- The creatinine-to-cystatin C ratio as a prognostic risk-stratification biomarker in chronic kidney disease.Frontiers in nutrition · 2026Article
- Sarcopenia index is a superior prognostic marker to creatinine-cystatin C ratio in older adults with hip fracture.Journal of orthopaedic surgery and research · 2025Article
- Association of Serum Creatinine-Cystatin C Ratio With Hospital-Associated Complications and Post-Discharge Mortality.Geriatrics & gerontology international · 2025Observational
- Creatinine-to-Cystatin C Ratio Combined with FIB-4 and ELF for Noninvasive Fibrosis Assessment in MASLD.International journal of molecular sciences · 2025Article
- Comparing Cystatin C Estimated GFR With Creatinine Estimated GFR in Acute Kidney Injury Recovery.Kidney international reports · 2025Article
- Monitoring Sarcopenia With Incretin Receptor Activator Treatment.Journal of diabetes · 2025Article
- Association of creatinine-to-cystatin C ratio with computed tomography measures of skeletal muscle quantity and quality: The multi-ethnic study of atherosclerosis.Clinical nutrition (Edinburgh, Scotland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Sarcopenia is a syndrome of decreased muscle mass and deficits in muscle strength and physical function. We aimed to investigate the relationship between creatinine/cystatin C ratio (CCR) and sarcopenia and the prognostic value of CCR in hospitalized patients. Materials and methods: We searched for relevant studies in PubMed, EMBASE, and the Cochrane Database up to August 25, 2022. Meta-analyses were performed to evaluate the relationship between CCR and skeletal muscle [computed tomography-assessed skeletal muscle (CTASM), muscle strength, and physical performance], prognosis and important clinical outcomes in hospitalized adults. The pooled correlation coefficient, the area under the receiver operating characteristic (ROC) curves, and hazard ratio (HR) together with their 95% confidence intervals (CIs) were calculated. We also conducted subgroup analyses to explore the sources of heterogeneity. Results: A total of 38 studies with 20,362 patients were eligible. These studies were of moderate to high quality. Our results showed that CCR was significant correlations with all CTASM types (Fisher's Conclusion: CCR could be a simple, economical, and effective screening tool for sarcopenia in hospitalized patients, and it is a helpful prognostic factor for mortality and other important clinical outcomes. Systematic review registration: https://inplasy.com/inplasy-2022-9-0097/, identifier INPLASY202290097.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.